Dr. Lynce is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000
Education & Training
MedStar Health Georgetown University/Washington Hospital CenterFellowship, Hematology and Medical Oncology, 2011 - 2014- MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 2008 - 2011
Certifications & Licensure
MA State Medical License 2020 - 2025
DC State Medical License 2008 - 2020
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Start of enrollment: 2018 May 21
- TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Start of enrollment: 2019 Apr 17
Publications & Presentations
PubMed
- Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy Rates.Anna Weiss, Maria Sol Rosito, Danielle Braun, Brenna Barton, Monica McGrath
Annals of Surgical Oncology. 2025-03-20 - 3 citationsImplantation of engineered adipocytes suppresses tumor progression in cancer models.Hai P Nguyen, Kelly An, Yusuke Ito, Bhushan N Kharbikar, Rory Sheng
Nature Biotechnology. 2025-02-04 - 1 citationsT Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.Nam Woo Cho, Sophia M Guldberg, Barzin Y Nabet, Jie Zeng Yu, Eun Ji Kim
Cancer Immunology Research. 2025-02-03
Journal Articles
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerRita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Authored Content
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020
Press Mentions
Inflammatory Breast Cancer Grant Allows Two Researchers to Test a New Tool for Diagnosing the Aggressive SubtypeMay 31st, 2022
Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBCFebruary 11th, 2020
Data Presented on PI3K Pathway Alterations at SABCS 2019December 10th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
